Study #2021-0296
AL101 prior to standard-of-care surgery in patients with Notch activated adenoid cystic carcinoma (ACC).
MD Anderson Study Status
Not Accepting
Treatment Agent
AL101
Description
This phase Ib trial studies the side effects and possible benefits of AL101 before surgery in treating patients with notch activated adenoid cystic cancer. AL101 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving AL101 before surgery may help to control adenoid cystic cancer that has a NOTCH pathway activation.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Adenoid Cystic Carcinoma, Metastatic Adenoid Cystic Carcinoma
Study phase:
Phase I
Physician name:
Renata Ferrarotto
Department:
Thoracic/Head & Neck Medical Oncology
For general questions about clinical trials:
1-844-285-5619
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.